Abstract
Objective
To find out seropositivity rates at 4-6 and 9-12 years of age; among those who received one-dose measles at 9 months and one-dose MMR at 15 months of age.
Methods
80 healthy children (53 males) at 4-6 or 9-12 years of age, attending outpatient department for vaccination were enrolled. Antibody titers were estimated using commercially available quantitative-IgG ELISA kits.
Results
The seropositivity rates against measles, mumps, rubella were 80% (40/50), 86% (43/50), and 96% (48/50), respectively at 4-6 years, and 83.3% (25/30), 96.7% (29/30) and 96.7% (29/30), respectively at 9-12 years of age.
Conclusion
Single dose of rubella vaccine seems to provide adequate long-term protection; however, measles vaccine requires more doses for similar protection.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
John TJ. The role of Indian Academy of Pediatrics in the Expanded Program of Immunization. Indian Pediatr. 1985;22:91–5.
Thapa A, Khanal S, Sharapov U, Swezy V, Sedai T, Dabbagh A, et al. Progress towards measles elimination-South-East Asia Region 2003-2013. MMWR Morb Mortal Wkly Rep. 2015;64:613–7.
WHO. Measles Vaccine: WHO position Paper. Wkly Epidemiol Rec.2009; 35: 84: 349-60.
Vashishtha VM, Yewale VN, Bansal CP, Mehta P. IAP perspectives on Measles and Rubella Elimination Strategies. Indian Pediatr. 2014;51:719–22.
Vashishtha VM, Choudhury P, Kalra A, Bose A, Thacker N, Yewale VN, et al. Indian Academy of Pediatrics (IAP) Recommended Immunization Schedule for children aged 0 through 18 years–India, 2014 and updates on Immunization. Indian Pediatr. 2014; 51: 785–800.
Verma S. IAP Immunization timetable 2012 clarifications. Indian Pediatr. 2012:49:997–8.
WHO. Measles Virus Vaccine: WHO Position Paper. Wkly Epidemiol Rec. 2009;84:349-360.
World Health Organization. The Immunological Basis for Immunization Series. Module 7, 8, 9: Measles, Mumps, Rubella updates 2009.
Job JS, John TJ, Joseph A. Antibody response to measles immunization in India. Bull World Health Organ. 1984;62:737–41.
Gomber S, Arora SK, Das S, Ramachandran VG. Immune response to second dose of MMR vaccine in Indian children. Indian J Med Res. 2011;134:302–6.
Raut SK, Kulkarni PS, Phadke MA, Jadhav SS, Kapre SV, Dhere RM, et al. Persistence of antibodies induced by measles-mumps-rubella vaccine in children in India. Clin Vaccine Immunol. 2007;14:1370–1.
Saffar MJ, Fathpour GR, Parsaei MR, Ajami A, Khalilian AR, Shojaei J, et al. Measles-Mumps-Rubella revaccination; 18 months vs 4-6 years of age: Potential impacts of schedule changes. J Trop Pediatr. 2011;57:347–51.
Pebody RG, Gay NJ, Hesketh LM, Vyse A, Morgan-Capner P, Brown DW, et al. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. Vaccine. 2002;20:1134–40.
Rager-Zisman B, Bazarsky E, Skibin A, Chammey S, Belmaker I, Shai I, et al. The effect of measles-mumpsrubella (MMR) immunization on the immune response of previously immunized primary school children. Vaccine. 2003;21:2580–8.
Johnson CE, Kumar ML, Whitwell JK, Staehle BO, Rome LP, Dinakar C, et al. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr Infect Dis J. 1996;15:687–92.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hansashree, P., Verma, S., Rawat, A. et al. Long-term Seroprotection Rates Following Second Dose of Measles as MMR Vaccine at 15 months in Indian Children. Indian Pediatr 55, 405–407 (2018). https://doi.org/10.1007/s13312-018-1282-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-018-1282-8